AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22659448 — intervention group
Group type: COMPARATOR
Intervention: Fluvirin® (control vaccine)
Number of subjects: 1507
Study 20513105 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training (SST)
Number of subjects: 62
Study 20513105 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 62
Study 20513105 — intervention group
Group type: COMPARATOR
Intervention: Reference intervention (REF)
Number of subjects: 62
Study 18829935 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (20 mL of 0.5% bupivacaine) along with standard pain management
Number of subjects: 54
Study 18829935 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management alone (typically intravenous narcotics)
Number of subjects: 54
Study 15812204 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core biopsy (including 2 additional median cores)
Number of subjects: 200
Study 15812204 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsy (6 cores)
Number of subjects: 200
Study 15812204 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core biopsy
Number of subjects: 200
Study 15812204 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsy
Number of subjects: 200
Study 12459648 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2, interferon-alpha, and cisplatin
Number of subjects: 35
Study 10333914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin injected at -30 min before meal
Number of subjects: 12
Study 10333914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin injected at -15 min before meal
Number of subjects: 12
Study 10333914 — intervention group
Group type: COMPARATOR
Intervention: Lispro insulin injected at 0 min (at meal)
Number of subjects: 12
Study 10333914 — intervention group
Group type: COMPARATOR
Intervention: Lispro insulin injected at +15 min after meal
Number of subjects: 12
Study 7503007 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 to 100 mg/day, titrated to blood pressure and plasma potassium)
Number of subjects: 42
Study 7503007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1959704 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (22 mumol.kg‐1.h‐1)
Number of subjects: 5
Study 1959704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30426192 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEA with PCEA with EA (group 1)
Number of subjects: 127
Study 30426192 — intervention group
Group type: COMPARATOR
Intervention: CSEA with PCEA (group 2)
Number of subjects: 127
Study 28857658 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg once daily, increased to 200 mg after 2 weeks)
Number of subjects: 41
Study 28857658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28857658 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 41
Study 26394126 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-h ENERGY® shot (5-HES)
Number of subjects: 24
Study 26394126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23415635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 60 μg
Number of subjects: 102
Study 23415635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 300 μg
Number of subjects: 102
Study 23415635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 600 μg
Number of subjects: 102
Study 21035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with high saturated fat diet (SE)
Number of subjects: 8
Study 21035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with high monounsaturated fat diet (UE)
Number of subjects: 8
Study 21035513 — intervention group
Group type: COMPARATOR
Intervention: Sedentary with high saturated fat diet (SS)
Number of subjects: 8
Study 21035513 — intervention group
Group type: COMPARATOR
Intervention: Sedentary with high monounsaturated fat diet (US)
Number of subjects: 8
Study 21035513 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (SE and UE)
Number of subjects: 8
Study 21035513 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SS and US)
Number of subjects: 8
Study 21035513 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 8
Study 21035513 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated or unsaturated fat diets
Number of subjects: 8
Study 19738091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 mug/kg/min)
Number of subjects: 487
Study 19738091 — intervention group
Group type: COMPARATOR
Intervention: Control (no dopamine treatment)
Number of subjects: 487
Study 18178916 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass sleeve
Number of subjects: 1
Study 15089903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high vegetable and fruit diet
Number of subjects: 119
Study 15089903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 119
Study 11226092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 31
Study 11226092 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 31
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical services (EMS) ambulance transport
Number of subjects: 37889
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage categories 1 and 2
Number of subjects: 37889
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage category 4 (pseudoemergency)
Number of subjects: 37889
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life support, referral cases, and ICU bed requirements
Number of subjects: 37889
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 37889
Study 9745163 — intervention group
Group type: EXPERIMENTAL
Intervention: Case disposition evaluation
Number of subjects: 37889
Study 7519132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 0.5 x 10(6) KIU/h continuous infusion)
Number of subjects: 109
Study 7519132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 109
Study 7519132 — intervention group
Group type: COMPARATOR
Intervention: DDAVP (0.3 micrograms/kg i.v. on completion of CPB)
Number of subjects: 109
Study 7519132 — intervention group
Group type: COMPARATOR
Intervention: DDAVP (two doses: first as in group B and an additional dose 6 hours after surgery)
Number of subjects: 109
Study 7519132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 109
Study 2846291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 55
Study 2846291 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 55
Study 1097149 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking marihuana
Number of subjects: 10
Study 1097149 — intervention group
Group type: COMPARATOR
Intervention: Smoking placebo marihuana
Number of subjects: 10
Study 31710176 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hard palate closure (EHPC) group
Number of subjects: 108
Study 31710176 — intervention group
Group type: COMPARATOR
Intervention: Late hard palate closure (LHPC) group
Number of subjects: 108
Study 30527940 — intervention group
Group type: COMPARATOR
Intervention: Use of one stent
Number of subjects: 2652
Study 30527940 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of two or three stents
Number of subjects: 2652
Study 30527940 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of multiple stents (two or three)
Number of subjects: 2652
Study 30527940 — intervention group
Group type: COMPARATOR
Intervention: Overall CAS procedures
Number of subjects: 2652
Study 28351159 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted support (Phoneme Factory Sound Sorter [PFSS] - Australian version]
Number of subjects: 63
Study 25944732 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-α (High Hb group)
Number of subjects: 321
Study 25944732 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-α (Low Hb group)
Number of subjects: 321
Study 25944732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stage 4 CKD)
Number of subjects: 321
Study 25726677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 156
Study 25726677 — intervention group
Group type: COMPARATOR
Intervention: Other fluoroquinolones
Number of subjects: 156
Study 21771973 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 0
Study 21771973 — intervention group
Group type: EXPERIMENTAL
Intervention: esRAGE
Number of subjects: 0
Study 21771973 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin, 10 mg daily
Number of subjects: 0
Study 18957811 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release nifedipine (nifedipine CR) plus valsartan
Number of subjects: 0
Study 18957811 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine plus valsartan
Number of subjects: 0
Study 17276962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 40
Study 17276962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17276962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 40
Study 12677545 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐hydroxybutyrate
Number of subjects: 28
Study 12677545 — intervention group
Group type: COMPARATOR
Intervention: chlorprothixene/phenobarbital
Number of subjects: 28
Study 11078308 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based combined walking and resistance exercise program
Number of subjects: 40
Study 8832446 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (convection)
Number of subjects: 47
Study 8832446 — intervention group
Group type: COMPARATOR
Intervention: Warmed cotton blankets (conduction)
Number of subjects: 47
Study 1427804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg (single oral dose)
Number of subjects: 260
Study 1427804 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G (2.4 or 5.0 mega units) plus probenecid 1 gram (single intramuscular and oral dose respectively)
Number of subjects: 260
Study 6535843 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional psychotherapy
Number of subjects: 0
Study 6535843 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment in the program
Number of subjects: 0
Study 31625480 — intervention group
Group type: COMPARATOR
Intervention: 2‐iminobiotin (2‐IB) 0.6 mg/kg, infused over periods between 15 min and 4 h, and repeated doses escalating from 0.6 mg/kg to 12 mg/kg every 4 h for 6 administrations.
Number of subjects: 18
Study 31625480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐iminobiotin (2‐IB) with Captisol® as a solubilizing agent.
Number of subjects: 18
Study 31625480 — intervention group
Group type: COMPARATOR
Intervention: Placebo, infused over the same periods as 2‐IB.
Number of subjects: 18
Study 31625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated iv dosing of 2‐IB in an acute peripheral hypoxic ischemia model.
Number of subjects: 18
Study 30125688 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily medication group (PrEP)
Number of subjects: 331
Study 29949330 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 0
Study 29949330 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (Control)
Number of subjects: 0
Study 24162556 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly exercise training (ME = 14) for 8 weeks
Number of subjects: 50
Study 24162556 — intervention group
Group type: COMPARATOR
Intervention: Equal attention without training (MC = 14)
Number of subjects: 50
Study 22875472 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive smoking prevention program
Number of subjects: 2
Study 22875472 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking prevention program
Number of subjects: 2
Study 20533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 200
Study 20533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (all doses)
Number of subjects: 200
Study 20533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 200
Study 20533546 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 200
Study 18272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical case management
Number of subjects: 252
Study 18272094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 252
Study 15877288 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d) for 6 months
Number of subjects: 0
Study 15877288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rosiglitazone)
Number of subjects: 0
Study 14749150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cobalamin (1000-microg p.o. once daily for 10 days, then once weekly for 4 weeks, then once monthly)
Number of subjects: 60
Study 14749150 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular cobalamin (1000-microg i.m. once daily for 10 days, then once weekly for 4 weeks, then once monthly)
Number of subjects: 60
Study 10642360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise in upright posture (85% peak oxygen consumption rate)
Number of subjects: 7
Study 10642360 — intervention group
Group type: COMPARATOR
Intervention: Control (supine posture)
Number of subjects: 7
Study 8859934 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 15
Study 8859934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 6.25, 12.5, or 25 mg/day
Number of subjects: 15
Study 8859934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 or 100 mg/day
Number of subjects: 15
Study 1516991 — intervention group
Group type: EXPERIMENTAL
Intervention: Asahi polyacrylonitrile membrane
Number of subjects: 7
Study 1516991 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone membrane
Number of subjects: 7
Study 1516991 — intervention group
Group type: COMPARATOR
Intervention: AN69 polyacrylonitrile membrane
Number of subjects: 7
Study 1516991 — intervention group
Group type: COMPARATOR
Intervention: Polyamide membrane
Number of subjects: 7
Study 6723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 0.5 g/kg body weight) at 21 degrees C
Number of subjects: 10
Study 6723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 0.5 g/kg body weight) at 30 degrees C
Number of subjects: 10
Study 6723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (BP; 1.0 g/kg body weight) at 21 degrees C
Number of subjects: 10
Study 30782909 — intervention group
Group type: EXPERIMENTAL
Intervention: Early de-escalation of empirical carbapenems guided by the βLACTA test results
Number of subjects: 0
Study 30782909 — intervention group
Group type: COMPARATOR
Intervention: Standard de-escalation of carbapenems after 48-72 hours based on the antibiogram results
Number of subjects: 0
Study 28625642 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE (cisplatin 25mg/m2 on days 1, 8; doxorubicin 40mg/m2 on day 1; etoposide 80mg/m2 on days 1‐3; vincristine 1mg/m2 on day 8 every 2 weeks)
Number of subjects: 75
Study 28625642 — intervention group
Group type: EXPERIMENTAL
Intervention: AP (amrubicin 40mg/m2 on days 1‐3 and cisplatin 60mg/m2 on day 1 every 3 weeks)
Number of subjects: 75
Study 25920401 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential antral PVI (CPVI) alone (minimal)
Number of subjects: 234
Study 25920401 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI with IVR ablation (maximal)
Number of subjects: 234
Study 25920401 — intervention group
Group type: COMPARATOR
Intervention: Minimal group (without IVR ablation)
Number of subjects: 234
Study 25920401 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal group (with IVR ablation)
Number of subjects: 234
Study 23981402 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385
Study 23981402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay Foot Manipulation (LFM)
Number of subjects: 385
Study 23981402 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 385
Study 21911616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (0.75 L, 9.3 mmol nitrate; H-BR)
Number of subjects: 9
Study 21911616 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (0.75 L, 0.006 mmol nitrate; H-PL)
Number of subjects: 9
Study 21911616 — intervention group
Group type: COMPARATOR
Intervention: Control (normoxia; CON)
Number of subjects: 9
Study 19234816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus morphine
Number of subjects: 50
Study 19234816 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 50
Study 17009531 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated method (operation + Chinese medicine + dexamethasone + vitamin E)
Number of subjects: 96
Study 17009531 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine + dexamethasone + vitamin E
Number of subjects: 96
Study 14643269 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (200mg orally 3 times a day)
Number of subjects: 145
Study 14643269 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200mg orally 3 times a day) plus enalapril (10mg twice a day)
Number of subjects: 145
Study 11211370 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive preventive intervention for maltreated infants and toddlers in foster care
Number of subjects: 0
Study 11211370 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (1991-1994)
Number of subjects: 0
Study 9455821 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ovarian follicular aspiration
Number of subjects: 31
Study 9455821 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspiration)
Number of subjects: 31
Study 7933438 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition including a conventional amino acid solution (control group)
Number of subjects: 17
Study 7933438 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition including the same amino acid solution supplemented with glycyl-glutamine (GLN group)
Number of subjects: 17
Study 3119449 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 79
Study 3119449 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 mcg)
Number of subjects: 79
Study 3119449 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg) in smokers
Number of subjects: 79
Study 3119449 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 mcg) in smokers
Number of subjects: 79
Study 30815556 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, nudge‐based risk communication intervention (n = 20)
Number of subjects: 40
Study 30815556 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 20)
Number of subjects: 40
Study 26526376 — intervention group
Group type: EXPERIMENTAL
Intervention: Burns (55 reported, 10% of all injuries)
Number of subjects: 5148
Study 26526376 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious burns (2340 estimated, 39 per 100,000 persons in 2003)
Number of subjects: 5148
Study 26526376 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged over 45 years
Number of subjects: 5148
Study 26526376 — intervention group
Group type: EXPERIMENTAL
Intervention: Burns involving ≥20% body surface area (19 burns, 35%)
Number of subjects: 5148
Study 25706948 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin orally preoperatively
Number of subjects: 48
Study 25706948 — intervention group
Group type: COMPARATOR
Intervention: 4 mg diazepam orally as placebo preoperatively
Number of subjects: 48
Study 23465098 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 105
Study 23465098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 105
Study 23465098 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CABG
Number of subjects: 105
Study 23465098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention on the saphenous vein graft
Number of subjects: 105
Study 21481151 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE)
Number of subjects: 157
Study 21481151 — intervention group
Group type: COMPARATOR
Intervention: Surgery (hysterectomy or myomectomy)
Number of subjects: 157
Study 19592103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RMS)
Number of subjects: 495
Study 16433711 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 272
Study 16433711 — intervention group
Group type: COMPARATOR
Intervention: NPH-based multiple daily insulin injections (MDI)
Number of subjects: 272
Study 12945134 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimetric electromagnetic radiation (MER) combined therapy
Number of subjects: 0
Study 12945134 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study 12945134 — intervention group
Group type: COMPARATOR
Intervention: Combinations with sinusoidal modulated currents
Number of subjects: 0
Study 12945134 — intervention group
Group type: COMPARATOR
Intervention: Placebo electromagnetic radiation
Number of subjects: 0
Study 12945134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with 5.6 mm radiation
Number of subjects: 0
Study 10618557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 1000
Study 10618557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9357123 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin administered twice a day
Number of subjects: 50
Study 9357123 — intervention group
Group type: COMPARATOR
Intervention: Control group (lente insulin)
Number of subjects: 50
Study 1534089 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg monthly combined with oral MPA 15 mg daily for 6 months
Number of subjects: 20